Skip to content
Screener

Neurocrine Biosciences NBIX Business Segments — R&D

Similar metrics at other companies

Immunovant, Inc. logo
IMVTReportable Segment — R&D
$29.22M-6.2%
Indivior Pharmaceuticals, Inc. logo
INDVReportable Segment — R&D
$16M-27.3%
Travere Therapeutics, Inc. logo
TVTXReportable Segment — R&D
$57.09M+21.8%
Evolus logo
EOLSReportable Segment — R&D
$1.89M+3.0%
Zevra Therapeutics, Inc. logo
ZVRAReportable Segment — R&D
$2.28M-2.5%
Zymeworks logo
ZYMEReportable Segment — R&D
$27.44M-20.4%

Other financials

Income statement

See full
Revenue$814.5M+42.2%
Gross profit$800.7M+42.1%
Operating income$193.4M+719%
Net income$197.9M+2,405%
EPS (diluted)$1.91+2,287%

Balance sheet

See full
Cash & equivalents$274.5M+35.8%
Total debt$463.5M-6.0%
Total equity$3.4B+34.4%
Total assets$4.9B+33.0%

Cash flow

See full
Operating cash flow$145.8M+125%
CapEx$9.1M-15.0%
Free cash flow$136.7M+153%

Valuation

See full
Market cap$16.25B+27.5%
Enterprise value$16.43B+26.9%
P/E24.3×-12.3×
P/S5.2×+0.2×

Profitability

See full
Gross margin98.2%-0.3pp
Operating margin25.4%+4.9pp
Net margin21.6%+8.9pp
FCF margin26.8%+6.4pp

Returns & leverage

See full
Return on equity22.5%+10.1pp
Debt / equity0.1×-0.1×
Current ratio2.9×-0.2×

Where this comes from

Reported directly by Neurocrine Biosciences in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:02 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000914475-26-000026
(in millions)Three Months Ended March 31, 20262025
Payroll and benefits84.575.0
Milestones22.645.4
Other research and development (2)41.134.9
Total research and development296.2263.2
Acquired in-process research and development21.20.1
Selling, general, and administrative318.5276.5
Gain on sale of business, net of transaction costs(28.6)—
Unrealized (gain) loss on equity investments(25.3)30.6

Item 1. Financial Statements

FAQ

What is Neurocrine Biosciences's business segments — R&D?
Neurocrine Biosciences (NBIX) reported business segments — R&D of $296.2M in Q1 2026.
How has Neurocrine Biosciences's business segments — R&D changed year-over-year?
Neurocrine Biosciences's business segments — R&D increased by 12.5% year-over-year, from $263.2M to $296.2M.
What is the long-term trend for Neurocrine Biosciences's business segments — R&D?
Over 3 years (2022 to 2025), Neurocrine Biosciences's business segments — R&D has grown at a 29.9% compound annual growth rate (CAGR), from $463.8M to $1.02B.
What does business segments — R&D mean?
Captures the ongoing investment in clinical trials, drug discovery, and scientific research necessary to advance the company's pipeline. High levels of spending reflect the company's commitment to long-term innovation and future product launches.

Ask your AI about Neurocrine Biosciences's business segments — r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude